HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX - Free Report) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $8.00 price target on the stock.
InflaRx Stock Performance
IFRX traded up $0.03 during trading on Thursday, reaching $2.55. 144,852 shares of the stock were exchanged, compared to its average volume of 182,677. The stock has a market cap of $150.09 million, a P/E ratio of -2.36 and a beta of 1.66. The stock's 50 day moving average price is $2.26 and its two-hundred day moving average price is $1.78. InflaRx has a twelve month low of $1.16 and a twelve month high of $2.82.
InflaRx Company Profile
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
See Also
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
